Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention

Background Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI). Aim We sought to describe the trends in uptake of the newer agents and analyse the clinical characteristics and short‐t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal medicine journal 2016-05, Vol.46 (5), p.559-565
Hauptverfasser:	Yudi, M. B., Clark, D. J., Farouque, O., Eccleston, D., Andrianopoulos, N., Duffy, S. J., Brennan, A., Lefkovits, J., Ramchand, J., Yip, T., Oqueli, E., Reid, C. M., Ajani, A. E.
Format:	Artikel
Sprache:	eng
Schlagworte:	acute coronary syndrome Acute Coronary Syndrome - mortality Acute Coronary Syndrome - therapy Adenosine - adverse effects Adenosine - analogs & derivatives Adenosine - therapeutic use Aged Aged, 80 and over antiplatelet agent Australia - epidemiology clopidogrel Comorbidity Female Hemorrhage - chemically induced Humans Male Middle Aged Multivariate Analysis Myocardial Infarction - chemically induced Percutaneous Coronary Intervention prasugrel Prasugrel Hydrochloride - adverse effects Prasugrel Hydrochloride - therapeutic use Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Registries ticagrelor Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!